RNA interference - Pipeline Insight, 2022
This report can be delivered to the clients within 72 hours
DelveInsight’s, “RNA interference - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in RNA interference pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
RNA interference: Overview
RNA interference (RNAi) or Post-Transcriptional Gene Silencing (PTGS) is a conserved biological response to double-stranded RNA that mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes. This natural mechanism for sequence-specific gene silencing promises to revolutionize experimental biology and may have important practical applications in functional genomics, therapeutic intervention, agriculture and other areas.
Function - RNA molecules play numerous roles in both normal cellular processes and disease states. Generally, those RNA molecules that do not take the form of mRNA are referred to as noncoding, because they do not encode proteins. The involvement of noncoding mRNAs in many regulatory processes, their abundance, and their diversity of functions has led to the hypothesis that an 'RNA world' may have preceded the evolution of DNA and proteins e-specific RNA degradation process (posttranscriptional gene silencing [PTGS]/RNA interference [RNAi]). RNA silencing is a novel gene regulatory mechanism that limits the transcript level by either suppressing transcription (transcriptional gene silencing [TGS]) or by activating a sequenc
RNA interference - RNA interference (RNAi) is a biological process by which double-stranded RNA (dsRNA) induces sequence-specific gene silencing by targeting mRNA for degradation. As a tool for knocking down the expression of individual genes post transcriptionally, RNAi has been widely used to study the cellular function of genes.
RNA interference Emerging Drugs Chapters
This segment of the RNA interference report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
RNA interference Emerging Drugs
Further product details are provided in the report……..
RNA interference: Therapeutic Assessment
This segment of the report provides insights about the different RNA interference drugs segregated based on following parameters that define the scope of the report, such as:
RNA interference: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses RNA interference therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging RNA interference drugs.
Report Highlights
Current Scenario and Emerging Therapies:
DelveInsight’s, “RNA interference - Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in RNA interference pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
RNA interference: Overview
RNA interference (RNAi) or Post-Transcriptional Gene Silencing (PTGS) is a conserved biological response to double-stranded RNA that mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes. This natural mechanism for sequence-specific gene silencing promises to revolutionize experimental biology and may have important practical applications in functional genomics, therapeutic intervention, agriculture and other areas.
Function - RNA molecules play numerous roles in both normal cellular processes and disease states. Generally, those RNA molecules that do not take the form of mRNA are referred to as noncoding, because they do not encode proteins. The involvement of noncoding mRNAs in many regulatory processes, their abundance, and their diversity of functions has led to the hypothesis that an 'RNA world' may have preceded the evolution of DNA and proteins e-specific RNA degradation process (posttranscriptional gene silencing [PTGS]/RNA interference [RNAi]). RNA silencing is a novel gene regulatory mechanism that limits the transcript level by either suppressing transcription (transcriptional gene silencing [TGS]) or by activating a sequenc
RNA interference - RNA interference (RNAi) is a biological process by which double-stranded RNA (dsRNA) induces sequence-specific gene silencing by targeting mRNA for degradation. As a tool for knocking down the expression of individual genes post transcriptionally, RNAi has been widely used to study the cellular function of genes.
RNA interference Emerging Drugs Chapters
This segment of the RNA interference report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
RNA interference Emerging Drugs
- Fitusiran: Alnylam Pharmaceuticals
- WVE 120102: WaVe life Sciences
Further product details are provided in the report……..
RNA interference: Therapeutic Assessment
This segment of the report provides insights about the different RNA interference drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on RNA interference
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical.
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
RNA interference: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses RNA interference therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging RNA interference drugs.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence RNA interference R&D. The therapies under development are focused on novel approaches for RNA interference.
- RNA interference Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing RNA interference drugs?
- How many RNA interference drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for RNA interference?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the RNA interference therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for RNA interference and their status?
- What are the key designations that have been granted to the emerging drugs?
- Alnylam Pharmaceuticals
- WaVe life Sciences
- Medesis Pharma
- Bio-Path Holdings
- Sirnaomics
- Arrowhead Pharmaceuticals
- Silence Therapeutics
- Dicerna Pharmaceuticals
- Novo Nordisk
- Eli Lilly and Company
- Ionis Pharmaceuticals
- Quark Pharmaceuticals
- ProQR Therapeutics
- Arbutus Biopharma
- Atugen AG
- Sylentis
- Bristol-Myers Squibb
- OliX Pharmaceuticals
- Janssen Pharmaceuticals
- Amgen
- miRagen Therapeutics
- Regulus Therapeutics
- Fitusiran
- WVE 120102
- siRNA therapeutic
- BP 1003
- STP 705
- Research programme: short interfering RNA-based therapeutics
- IONIS AGT LRx
- QPI 1007
- Teprasiran
- Eluforsen
- RG 6346
- AB 729
- QR-421a
- Sepofarsen
- PF 4523655
- ALN VSP
- Atu027
- Bamosiran
- BMS 986263
- ARO APOC3
- Tivanisiran
- OLX 101A
- TAK 999
- Nedosiran
- Olpasiran
- Remlarsen
- MRG 110
- Lademirsen
Introduction
Executive Summary
RNA interference: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
RNA interference – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
RNA interference companies’ collaborations, Licensing, Acquisition -Deal Value Trends
RNA interference Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Fitusiran: Alnylam Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IONIS AGT LRx : Ionis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
QR-421a: ProQR Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BP 1003: Bio-Path Holdings
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
RNA interference Key Companies
RNA interference Key Products
RNA interference- Unmet Needs
RNA interference- Market Drivers and Barriers
RNA interference- Future Perspectives and Conclusion
RNA interference Analyst Views
RNA interference Key Companies
Appendix
Executive Summary
RNA interference: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
RNA interference – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
RNA interference companies’ collaborations, Licensing, Acquisition -Deal Value Trends
RNA interference Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Fitusiran: Alnylam Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
IONIS AGT LRx : Ionis Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
Comparative Analysis
QR-421a: ProQR Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
BP 1003: Bio-Path Holdings
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
RNA interference Key Companies
RNA interference Key Products
RNA interference- Unmet Needs
RNA interference- Market Drivers and Barriers
RNA interference- Future Perspectives and Conclusion
RNA interference Analyst Views
RNA interference Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for RNA interference
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for RNA interference
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for RNA interference
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for RNA interference
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
